Showing results (101-110 of 312) with videos related to
Sort By:
Pageof 32
Cureus|May 9, 2024
Evaluating Peer Review of Palliative Radiation Plans at a Canadian Tertiary Care Cancer CenterStephanie Gulstene, Adam Mutsaers, Melissa O'Neil, et al.The Oncologist|April 28, 2022
Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical BenefitLori J Wirth, Cosimo Durante, Duncan J Topliss, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2008
Nomograms to predict serious adverse events in phase II clinical trials of molecularly targeted agentsGregory R Pond, Lillian L Siu, Malcolm Moore, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 28, 2004
Prediction of radiation pneumonitis by dose - volume histogram parameters in lung cancer--a systematic reviewGeorge Rodrigues, Michael Lock, David D'Souza, et al.The Lancet. Oncology|May 28, 2013
Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 studyYoo-Joung Ko, Christine M Canil, Som D Mukherjee, et al.Medical Physics|July 27, 2012
Hyperpolarized (3)He pulmonary functional magnetic resonance imaging prior to radiation therapyLindsay Mathew, Jake Vandyk, Roya Etemad-Rezai, et al.Medical Physics|December 11, 2013
Inter-slice bidirectional registration-based segmentation of the prostate gland in MR and CT image sequencesFarzad Khalvati, Aryan Salmanpour, Shahryar Rahnamayan, et al.Cureus|December 7, 2023
Clinical Presentation and Genomic Analysis of HPV-Related Squamous Cell Carcinoma of the Larynx in Two Young Female PatientsZahra Taboun, Peter Zeng, Jasna Deluce, et al.Acta Oncologica (Stockholm, Sweden)|April 1, 2015
Identification and survival outcomes of a cohort of patients with cancer of unknown primary in Ontario, CanadaChong S Kim, Malek B Hannouf, Sisira Sarma, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combinationCarol A Townsley, Gregory R Pond, Amit M Oza, et al.Pageof 32